Showing results (1-10 of 76) with videos related to
Sort By:
Pageof 8
Hematology. American Society of Hematology. Education Program|December 10, 2013
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?Peter Paschka, Konstanze DöhnerHematology. American Society of Hematology. Education Program|February 20, 2015
Intermediate-risk acute myeloid leukemia therapy: current and futureKonstanze Döhner, Peter PaschkaActa Haematologica|June 5, 2004
Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistancePeter Paschka, Kirsten Merx, Andreas HochhausHematological Oncology|December 17, 2009
The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemiaCarolyn Owen, Jude Fitzgibbon, Peter PaschkaMicroorganisms|December 23, 2022
Single Center Experience Using Monoclonal COVID-19 Antibodies in the Management of Immunocompromised Patients with COVID-19David Klank, Bernd Claus, Raoul Bergner, et al.Current Opinion in Oncology|October 9, 2008
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaKrzysztof Mrózek, Guido Marcucci, Peter Paschka, et al.European Journal of Haematology|March 16, 2021
The urine light chain/glomerular filtration rate (GFR) quotient shows a high sensitivity and specificity to detect cast nephropathy in monoclonal light chain diseaseRaoul Bergner, Martin Hoffmann, Michael Uppenkamp, et al.Biomedicines|May 25, 2024
The Urine Light Chain/eGFR Quotient as a Tool to Rule out Cast Nephropathy in Myeloma-Associated Kidney FailureDavid Klank, Christian Löffler, Julian Friedrich, et al.Blood|September 9, 2006
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Krzysztof Mrózek, Guido Marcucci, Peter Paschka, et al.Pageof 8